Perceptive Advisors LLC Provention Bio, Inc. Transaction History

Perceptive Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.65 - $7.3 $2.48 Million - $4.97 Million	-680,821 Reduced 86.01%	110,728 $443,000
Q1 2022 May 16, 2022	SELL	$3.4 - $7.88 $533,568 - $1.24 Million	-156,932 Reduced 16.55%	791,549 $5.79 Million
Q2 2021 Aug 16, 2021	SELL	$6.71 - $11.04 $12.8 Million - $21 Million	-1,903,577 Reduced 66.74%	948,481 $8 Million
Q1 2021 May 17, 2021	SELL	$10.12 - $19.45 $13.9 Million - $26.7 Million	-1,372,331 Reduced 32.49%	2,852,058 $29.9 Million
Q4 2020 Feb 16, 2021	SELL	$11.79 - $18.94 $487,186 - $782,638	-41,322 Reduced 0.97%	4,224,389 $71.6 Million
Q3 2020 Nov 16, 2020	SELL	$10.34 - $15.2 $2.69 Million - $3.95 Million	-260,000 Reduced 5.74%	4,265,711 $54.7 Million
Q2 2020 Aug 14, 2020	BUY	$7.81 - $17.0 $11.8 Million - $25.7 Million	1,514,137 Added 50.28%	4,525,711 $63.9 Million
Q1 2020 May 15, 2020	BUY	$5.42 - $17.75 $487,800 - $1.6 Million	90,000 Added 3.08%	3,011,574 $27.7 Million
Q4 2019 Feb 14, 2020	BUY	$5.84 - $14.9 $13.2 Million - $33.6 Million	2,255,252 Added 338.46%	2,921,574 $43.5 Million
Q3 2019 Nov 14, 2019	BUY	$6.83 - $13.0 $4.55 Million - $8.66 Million	666,322 New	666,322 $4.55 Million

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.